Livermax Duo
Contributes to normal metabolism of fatty acids
Contributes to normal energy-yielding metabolism and helps to detoxify the liver (EFSA claims)
Non-alcoholic fatty liver disease (NAFLD)
Progression to
Non-alcoholic steatohepatitis (NASH)
The main guidelines recommend lifestyle changes, including exercise and correct diet to promote weight loss, while no conclusive evidence is available of drug treatments
NON-ALCOHOLIC FATTY LIVER DISEASE: RISK FACTORS
Obesity, free fatty acids, dietary factors, insulin resistance and excess visceral fat are associated with the development of (1) NAFLD.
Many factors are hypothesized to play a role in the transition to (2) NASH, including:
Preclinical studies have shown an association between menopause and the progression of NAFLD due to the hormonal changes suffered at this stage.
Gut-liver axis is a close anatomical and functional connection of the gastrointestinal tract (GIT) and liver.
Disruption of this axis has an essential role in the pathogenesis of conditions as NAFLD.
This disruption includes:
LiverMax Duo offers a complete formula to control the metabolic factors that lead to NAFLD (prevention), as well as controlling the disease once it is established and its progression to NASH. Thanks to the synergic effect of its components, our solution promotes liver health from different angles and assures a correct function of the gut-liver axis.
Innovate Cap in Cap System
An external capsule that delivers the ingredient at the intestinal stage:
✓ Triple synbiotic protected from interactions with components of the inner capsule to guarantee its stability.
✓ The triple synbiotic corrects the gut microbiota imbalance (dysbiosis).
✓ Directly delivered at the intestine to colonize the gut.
Innovate Cap in Cap System
An internal capsule that delivers the ingredients at the intestinal stage:
✓ Intestinal absorption of the components.
✓ Choline is generally absorbed in the small intestine by sodium-independent carrier mediated transport, delivering it directly at its preferential absorption site.
PRODUCT'S MECHANISMS OF ACTION: FATTY LIVER DISEASE
✓Lactobacillus reuteri (probiotic+ postbiotic):
✓ FOS: synergistic effect on the growth of the probiotic.
✓ Synbiotic: Modulation of metabolic syndrome symptoms. Maintains a normal microbiota reducing gut permeability.
PRODUCT'S MECHANISMS OF ACTION: FATTY LIVER DISEASE
✓ Contributes to normal lipid metabolism.
✓ Maintains normal liver function.
✓ Gut-liver axis: Restoring choline levels in those cases of SIBO where there is a high demand of this nutrient.
PRODUCT'S MECHANISMS OF ACTION: FATTY LIVER DISEASE
Reduces the formation of lipotoxic lipids and oxidized phopholipids, and limits oxidative stress thanks to:
✓ Antioxidant properties. Mitigates lipid peroxidation and the production of free radical injury.
✓ Anti-hepatotoxic activity induced by drugs. Also, it reduces ischemic damage to the hepatic cells.
✓ Anti-inflammatory activity: reduction of liver enzyme levels, cytokine release and serum biomarkers.
Product's Mechanisms of Action: Fatty Liver Disease
✓ Zinc deficiency induces insulin resistance.
✓ Reduces oxidative stress.
✓ Low levels correlate with higher severity of liver steatosis.
PRODUCT'S MECHANISMS OF ACTION: FATTY LIVER DISEASE
✓ Cofactor of lipid metabolism.
✓ Reduction of cardiovascular disease by affecting lipid metabolism.
✓ Low levels are correlated with NAFLD.
A powerful aid for a healthy gut-liver axis
1. Indications: For general population and menopausal women for:
References
1. Werlinger, P. et al. Lactobacillus reuteri MJM60668 Prevent Progression of Non-Alcoholic Fatty Liver Disease through Anti-Adipogenesis and Anti-Inflammatory Pathway. Microorganisms 10, (2022).
2. Chang, T. Y. et al. Optimal Dietary Intake Composition of Choline and Betaine Is Associated with Minimized Visceral Obesity-Related Hepatic Steatosis in a Case-Control Study. Nutrients 14, (2022).
3. Salvoza, N., Giraudi, P. J., Tiribelli, C. & Rosso, N. Natural Compounds for Counteracting Nonalcoholic Fatty Liver Disease (NAFLD): Advantages and Limitations of the Suggested Candidates. International Journal of Molecular Sciences vol. 23 Preprint at https://doi.org/10.3390/ijms23052764 (2022).
4. Navarro, V. J. et al. Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: A randomized, double-blind, placebo controlled trial. PLoS One 14, (2019).
5. Khan, A. et al. Understanding the effects of gut microbiota dysbiosis on nonalcoholic fatty liver disease and the possible probiotics role: Recent updates. International Journal of Biological Sciences vol. 17 818–833 Preprint at https://doi.org/10.7150/ijbs.56214 (2021).
6. Kobayashi, T. et al. Vitamin B6 efficacy in the treatment of nonalcoholic fatty liver disease: an openlabel, singlearm, singlecenter trial. J. Clin. Biochem. Nutr 68, 181–186 (2021).
7. Calani, L., Brighenti, F., Bruni, R. & Del Rio, D. Absorption and metabolism of milk thistle flavanolignans in humans. Phytomedicine 20, 40–46 (2012).
8. Abenavoli, L. et al. Milk thistle (Silybum marianum): A concise overview on its chemistry, pharmacological, and nutraceutical uses in liver diseases. Phytotherapy Research vol. 32 2202–2213 Preprint at https://doi.org/10.1002/ptr.6171 (2018).
9, Ferolla, S. M. et al. Beneficial effect of synbiotic supplementation on hepatic steatosis and anthropometric parameters, but not on gut permeability in a population with nonalcoholic steatohepatitis. Nutrients 8, (2016).
10. Bence, K. K. & Birnbaum, M. J. Metabolic drivers of non-alcoholic fatty liver disease. Molecular Metabolism vol. 50 Preprint at https://doi.org/10.1016/j
.molmet.2020.101143 (2021).
11. Scientific Opinion on the substantiation of health claims related to choline and contribution to normal lipid metabolism (ID 3186), maintenance of normal homocysteine metabolism (ID 3090), maintenance of normal liver function (ID 1501), contribution to normal lipid metabolism (ID 1503) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 9, (2011).
12. Liu, X., Shen, H., Chen, M. & Shao, J. Clinical Relevance of Vitamins and Carotenoids With Liver Steatosis and Fibrosis Detected by Transient Elastography in Adults. Front Nutr 8, (2021).
13. Hackett, E. S., Twedt, D. C. & Gustafson, D. L. Milk Thistle and Its Derivative Compounds: A Review of Opportunities for Treatment of Liver Disease. Journal of Veterinary Internal Medicine vol. 27 10–16 Preprint at https://doi.org/10.1111/jvim.12002 (2013).
14. Ferro, Y. et al. A new nutraceutical (Livogen Plus®) improves liver steatosis in adults with non-alcoholic fatty liver disease. J Transl Med 20, (2022).
15. Nehmi-Filho, et al. Novel nutraceutical supplements with yeast β-glucan, prebiotics, minerals, and Silybum marianum (silymarin) ameliorate obesity-related metabolic and clinical parameters: A double-blind randomized trial. Frontiers in endocrinology, 13, 1089938. https://doi.org/10.3389/fendo.
2022.1089938. (2023)
16. Venetsanaki V, Polyzos SA. Menopause and Non-Alcoholic Fatty Liver Disease: A Review Focusing on Therapeutic Perspectives. Curr Vasc Pharmacol. 17(6):546-555. doi:10.2174/1570161116666180712112949. (2019).
Nutraceutical Research and Development Company
We create innovative, scientifically proven solutions with specific benefits designed to complement or substitute pharmaceuticals.
Our mission is to enhance people’s well-being through nutraceutical products with proven benefits and the backing of scientific research.
